Rituximab-abbs (Truxima) vs SAR448501
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline
Rituximab-abbs (Truxima)
Marketed by Celltrion and partners
NCT02149121 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with an adequately sized population (384 enrolled) that pre-specified formal equivalence margins for both its pharmacokinetic and its clinical disease-activity (DAS28-CRP) primary endpoints, and every comparison landed entirely within the required margin, meaning the biosimilar demonstrated therapeutic equivalence to the reference product on a validated hard clinical measure of rheumatoid arthritis activity, not just a proxy lab value.
Reported efficacy
Analysis of Serum AUC0-last of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA); Analysis of Serum AUC0-inf of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Serum Cmax of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Change From Baseline of DAS28 (CRP) at Week 24 (ANCOVA) (at Week 24 of the Main Study Period): Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%). (met)
Result source: NCT02149121
SAR448501
Developed by Sanofi
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2029 · NCT06647069 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Rituximab-abbs (Truxima) | SAR448501 |
|---|---|---|
| ACR20 | —Not reported | —Not reported |
| ACR50 | —Not reported | —Not reported |
| ACR70 | —Not reported | —Not reported |
| DAS28-CRP remission | —Not reported | —Not reported |
| HAQ-DI, change | —Not reported | —Not reported |
| Modified Sharp score, change | —Not reported | —Not reported |
ACR20
- Rituximab-abbs (Truxima)
- —Not reported
- SAR448501
- —Not reported
ACR50
- Rituximab-abbs (Truxima)
- —Not reported
- SAR448501
- —Not reported
ACR70
- Rituximab-abbs (Truxima)
- —Not reported
- SAR448501
- —Not reported
DAS28-CRP remission
- Rituximab-abbs (Truxima)
- —Not reported
- SAR448501
- —Not reported
HAQ-DI, change
- Rituximab-abbs (Truxima)
- —Not reported
- SAR448501
- —Not reported
Modified Sharp score, change
- Rituximab-abbs (Truxima)
- —Not reported
- SAR448501
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SAR448501: no structured comparison results are available for Rheumatoid Arthritis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Rituximab-abbs (Truxima): 4 of 4 rows · SAR448501: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Rituximab-abbs (Truxima) |
|---|---|
| Dropout rate | 13%CT-P10 (Main Study Period) NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more result—CT-P10/CT-P10 (Extension Study Per NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Discontinued due to AEs | 1.2%CT-P10 (Main Study Period) NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more result—CT-P10/CT-P10 (Extension Study Per NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Serious AEs | 8.1%CT-P10 (Main Study Period) NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more result3.3%CT-P10/CT-P10 (Extension Study Per NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
| Most frequent reported AEs | infusion-related reaction 20.5% upper respiratory tract infection 14.9% urinary tract infection 9.3% NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 show 1 more resultupper respiratory tract infection 8.2% urinary tract infection 6.6% infusion-related reaction 3.3% NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Rituximab-abbs (Truxima)
show 3 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rituximab-abbs (Truxima)'s landscape · SAR448501's landscape